<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143855</url>
  </required_header>
  <id_info>
    <org_study_id>HM20008062</org_study_id>
    <secondary_id>U54DA038999</secondary_id>
    <nct_id>NCT03143855</nct_id>
  </id_info>
  <brief_title>Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder</brief_title>
  <official_title>Phase I Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to develop initial human data on effects of novel&#xD;
      compounds on safety (interactions with oxycodone) and efficacy (subjective response to&#xD;
      oxycodone) in non-treatment seeking opioid use disorder subjects. The compound to be studied&#xD;
      will be the 5-HT2CR agonist lorcaserin. There are no known or reported adverse interactions&#xD;
      between lorcaserin and oxycodone or other opioids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lorcaserin is a serotonin (5-HT) 2C receptor agonist (Trade Name Belviq) approved for&#xD;
      treatment of obesity. The study teams's preclinical research collaborators and others have&#xD;
      shown that lorcaserin and other 5-HT2CR agonists have been shown to reduce drugs of abuse&#xD;
      self-administration and cue reactivity in rodents including cocaine and nicotine. Recently,&#xD;
      this data has been expanded to opioids. Rats trained to self-administer oxycodone showed a&#xD;
      significant reduction in self-administration and oxycodone cue induced lever presses after&#xD;
      lorcaserin administration.&#xD;
&#xD;
      This is a single center, double-blind, placebo-controlled, randomized, 1b/2a study. 18&#xD;
      subjects are planned. The following treatment regimens will be used:&#xD;
&#xD;
      Lorcaserin will be administered at a dose of 10mg twice daily. Placebo or Comparator -&#xD;
      identical placebo capsules administered at the same time as lorcaserin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2017</start_date>
  <completion_date type="Actual">April 5, 2019</completion_date>
  <primary_completion_date type="Actual">April 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale</measure>
    <time_frame>Baseline to day 5</time_frame>
    <description>Drug liking is measured on a 100 millimeter visual analog rating with one end of the line representing a score of 0 for &quot;not at all&quot; and the other end being a score of 100 or extremely. Participants complete the rating 45 minutes after a 20 mg dose of oxycodone at baseline and after after 5 days of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Opioid Abuse</condition>
  <condition>Opioid Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days</description>
    <arm_group_label>Lorcaserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered twice daily for for 5 days</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, subjects must:&#xD;
&#xD;
          1. Males and females between 18 and 70 years-of-age.&#xD;
&#xD;
          2. Understand the study procedures and provide written informed consent.&#xD;
&#xD;
          3. Meet current DSM-5 criteria for opioid use disorder, at least moderate severity, but&#xD;
             are not seeking treatment.&#xD;
&#xD;
          4. Have at least one positive urine drug screen for opioids during screening to document&#xD;
             opioid use.&#xD;
&#xD;
          5. Have no clinically significant abnormalities in the judgment of the study physician in&#xD;
             hematology and chemistry laboratory tests including liver function tests.&#xD;
&#xD;
          6. Have no contraindications for study participation as determined by medical history and&#xD;
             physical examination.&#xD;
&#xD;
          7. Be able to demonstrate an understanding of study procedures and follow instructions&#xD;
             including behavioral laboratory testing.&#xD;
&#xD;
          8. No pregnant or nursing women will be permitted in the study, and women must either be&#xD;
             unable to conceive (i.e., surgically sterilized, sterile, or postmenopausal) or be&#xD;
             using a reliable form of contraception (e.g., abstinence, birth control pills,&#xD;
             intrauterine device with spermicide, or condoms). Men will be advised to use condoms.&#xD;
             All females must provide negative pregnancy urine tests before study entry, at each&#xD;
             visit during the study, and at the end of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In order to participate in the study, subjects must not:&#xD;
&#xD;
          1. Meet current DSM-5 diagnosis of any psychoactive substance use disorder other than&#xD;
             opioids, marijuana, cocaine or nicotine. Diagnosis of mild to moderate use disorder&#xD;
             for alcohol will not be considered exclusionary (SCID).&#xD;
&#xD;
          2. Have a current DSM-5 axis I psychiatric disorder other than substance use disorder&#xD;
             including but not limited to Bipolar Disorder, Major Depressive Disorder, ADHD, or&#xD;
             Schizophrenia or a neurological disorder requiring ongoing treatment and/or making&#xD;
             study participation unsafe.&#xD;
&#xD;
          3. Have any previous medically adverse reaction to oxycodone or other opioids or&#xD;
             lorcaserin.&#xD;
&#xD;
          4. Have any untreated clinically significant medical disorder including cardiovascular,&#xD;
             pulmonary, CNS, hepatic, or renal disorder.&#xD;
&#xD;
          5. Have a history of seizures (excluding childhood febrile seizures), or loss of&#xD;
             consciousness from traumatic injury for more than 30 minutes.&#xD;
&#xD;
          6. Have significant current suicidal or homicidal ideation or a history of suicide&#xD;
             attempt within the past 6 months.&#xD;
&#xD;
          7. Have conditions of probation or parole requiring reports of drug use to officers of&#xD;
             the court.&#xD;
&#xD;
          8. Have impending incarceration.&#xD;
&#xD;
          9. Have a positive HIV test by self-report or history.&#xD;
&#xD;
         10. Be pregnant or nursing or not using a reliable form of contraception if able to&#xD;
             conceive. All females must provide negative pregnancy urine tests at screening, and&#xD;
             daily after hospital admission.&#xD;
&#xD;
         11. Have any other illness, or condition, which in the opinion of the PI would preclude&#xD;
             safe and/or successful completion of the study.&#xD;
&#xD;
         12. Have taken any investigational drug within 90 days prior to baseline.&#xD;
&#xD;
         13. Have an allergy to lorcaserin or oxycodone.&#xD;
&#xD;
         14. Have taken or are currently taking drugs that are know to inhibit cytochrome P450,&#xD;
             CYP3A or CYP2D6.&#xD;
&#xD;
         15. ECG with QTc &gt; 440ms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick G Moeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxycodone</keyword>
  <keyword>lorcaserin</keyword>
  <keyword>Belviq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03143855/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03143855/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>32 participants signed the consent form however 5 participants were no shows for the initial visit at which ranndomization occurred.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lorcaserin</title>
          <description>Lorcaserin: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Placebo: Placebo will be administered twice daily for for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant experienced withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lorcaserin</title>
          <description>Lorcaserin: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Placebo: Placebo will be administered twice daily for for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="10.2"/>
                    <measurement group_id="B2" value="46" spread="8.8"/>
                    <measurement group_id="B3" value="48" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale</title>
        <description>Drug liking is measured on a 100 millimeter visual analog rating with one end of the line representing a score of 0 for &quot;not at all&quot; and the other end being a score of 100 or extremely. Participants complete the rating 45 minutes after a 20 mg dose of oxycodone at baseline and after after 5 days of treatment.</description>
        <time_frame>Baseline to day 5</time_frame>
        <population>Males and Females between ages 18 and 70 who meet criteria for opioid use disorder, at least moderate severity, but are not seeking treatment. Subjects diagnosed with a current psychiatric disorder or mental disorder including cardiovascular, pulmonary, CNS, hepatic or renal disorder are excluded from participation.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin</title>
            <description>Lorcaserin: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Placebo: Placebo will be administered twice daily for for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale</title>
          <description>Drug liking is measured on a 100 millimeter visual analog rating with one end of the line representing a score of 0 for &quot;not at all&quot; and the other end being a score of 100 or extremely. Participants complete the rating 45 minutes after a 20 mg dose of oxycodone at baseline and after after 5 days of treatment.</description>
          <population>Males and Females between ages 18 and 70 who meet criteria for opioid use disorder, at least moderate severity, but are not seeking treatment. Subjects diagnosed with a current psychiatric disorder or mental disorder including cardiovascular, pulmonary, CNS, hepatic or renal disorder are excluded from participation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.81" spread="31.7"/>
                    <measurement group_id="O2" value="-9.67" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lorcaserin</title>
          <description>Lorcaserin: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Placebo: Placebo will be administered twice daily for for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <description>Participant experienced withdrawal symptoms and receive Zofran. We felt it was not related to the study drug but was related to the participant taking more opioids than he told us which led to his withdrawal symptoms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. F. Gerard Moeller</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4134</phone>
      <email>fgmoeller@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

